VivoSeq
Other

Polymyalgia Rheumatica

27

Pipeline Programs↗

8

Active Trials↗

16

Companies Involved↗

Polymyalgia Rheumatica is an emerging landscape with 27 programs across 16 companies. The most active players are Sparrow Pharmaceuticals, AbbVie, Iovance Biotherapeutics, Inc.. 2 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

15/100

Mech. Concentration

21/100

Completion Rate

72/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sparrow Pharmaceuticals

2 programs

Phase 2AbbVie logo

AbbVie

2 programs

Phase 2I

Iovance Biotherapeutics, Inc.

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2E

Essen Biotech

1 program

Phase 2Roche logo

Roche

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

63%

Small molecule

19 of 30 classified programs — the dominant modality here.

37%ALL OTHERSMonoclonal antibody723%Protein / enzyme413%

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 97% of 32 pipeline programs.

Analysis

Trial Status

31

clinical trials

Completed13 · 42%
Unknown status5 · 16%
Terminated4 · 13%
Recruiting4 · 13%
Not yet recruiting2 · 6%
Active, not recruiting2 · 6%
Other1 · 3%

Clinical Trials

Trial Activity

31 trials

Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)
Recruiting·—·N/A·NCT06609668·78 enrolled
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Recruiting·Novartis logoNovartis·Phase 3·NCT06331312·288 enrolled
Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica
Recruiting·ZZhejiang University·Phase 3·NCT06172361·98 enrolled
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Each of Two Dose Levels of Sarilumab in Adults With Early Polymyalgia Rheumatica
Recruiting·Sanofi logoSanofi·Approved·NCT07286214·300 enrolled
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
Active, not recruiting·—·Phase 3·NCT05533164·174 enrolled
An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica
Active, not recruiting·RR-Pharm·Phase 3·NCT07670546·125 enrolled
Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07266168·80 enrolled
Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
Not yet recruiting·UUniversity Hospital, Brest·Phase 3·NCT07279688·140 enrolled
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed
Completed·—·Phase 3·NCT05533125·114 enrolled
BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica
Completed·UUniversity Hospital, Brest·Phase 2·NCT04027101·34 enrolled
Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica
Completed·RRenJi Hospital·Phase 2·NCT04799262·14 enrolled
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Completed·UUniversity Hospital, Brest·Phase 3·NCT02908217·113 enrolled
Study of Tocilizumab to Treat Polymyalgia Rheumatica
Completed·HHospital for Special Surgery, New York·Phase 2·NCT01396317·10 enrolled
Timed Release Tablet Prednisone in Polymyalgia Rheumatica
Completed·UUniversity Hospitals Bristol and Weston NHS Foundation Trust·Phase 2/3·NCT00836810·12 enrolled
Tocilizumab Effect iN pOlymyalgia Rheumatica
Completed·UUniversity Hospital, Brest·Phase 2·NCT01713842·21 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)